To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

NCT05169801 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer(NSCLC)

Interventions

DRUG: BP102, paclitaxel, carboplatin
DRUG: Avastin®, paclitaxel, carboplatin

Sponsor

Jiangsu HengRui Medicine Co., Ltd.